Insider Trading › FATE › Insiders
FATE THERAPEUTICS INC
FATE·Nasdaq·
United States·Insider activity
United States·Insider activity$2.29
-0.14 (-5.76%)
Close · Oct 6, 2026 · Close Prices from Tiingo.com
FATE
Insider purchases and sales on the price
Nasdaq 100S&P 500
Filings
Default90D1Y5YALL
FATES&P 500 (rebased)
Insider BuyInsider SellForm 144 · planned sale
Loading price history…
Daily closes, adjusted for splits and dividends · Close Prices from Tiingo.comHover a marker, every one is a filing · move across the line for the crosshair
In the last 180 days, FATE insiders filed 0 purchases ($0) and 4 sales ($306K) on the open market, by 2 insiders. Newest filing Aug 5, 2026 (2 months ago).
Net Insider Buying by Quarter
Shares bought (+) or sold (−) on the open market by FATE insiders · Form 4 · last two years
On Record
$0Purchases · 180 days
$306KSales · 180 days
408Open-market transactions on record
2Insiders filing · 180 days
Purchases (code P) and sales (code S) of FATE common stock reported on Form 4, with Form 5 annual catch-ups. Grants, option exercises, gifts and tax withholding are not shown. Dollars are shares × the stated price; a price outside anything the stock traded at that day is withheld (n/c).
Insider Transactions
408 on record · newest trade first · the newest 300 shown
AllPurchasesSalesOfficers & directors
| Insider | Type | Shares | Price | Value | Held after | Traded | Filed | |
|---|---|---|---|---|---|---|---|---|
| TAHL CINDYSee Remarks | Sale | −38.8K | $2.46 | $95K | 589.4Kdirect | Aug 4, 2026 | Aug 5, 2026 | Form 4 ↗ |
| Valamehr BahramPresident and CEO · Director | Sale | −43.9K | $2.46 | $108K | 591.8Kdirect | Aug 4, 2026 | Aug 5, 2026 | Form 4 ↗ |
| TAHL CINDYSee Remarks | Sale | −25.6K | $1.88 | $48K | 628.2Kdirect | May 20, 2026 | May 21, 2026 | Form 4 ↗ |
| Valamehr BahramPresident and CEO · Director | Sale | −28.9K | $1.88 | $54K | 635.8Kdirect | May 20, 2026 | May 21, 2026 | Form 4 ↗ |
| TAHL CINDYSee Remarks | Sale | −10.6K | $1.06 | $11K | 387.1Kdirect | Jan 9, 2026 | Jan 12, 2026 | Form 4 ↗ |
| Valamehr BahramPresident and CEO · Director | Sale | −5,190 | $1.07 | $6K | 329.7Kdirect | Jan 9, 2026 | Jan 12, 2026 | Form 4 ↗ |
| TAHL CINDYSee Remarks | Sale | −9,037 | $1.06 | $10K | 397.7Kdirect | Aug 4, 2025 | Aug 5, 2025 | Form 4 ↗ |
| Valamehr BahramPresident and CEO · Director | Sale | −14.5K | $1.06 | $15K | 334.9Kdirect | Aug 4, 2025 | Aug 5, 2025 | Form 4 ↗ |
| Bressi Jerome CharlesSee Remarks | Sale | −5,980 | $1.55 | $9K | 270.2Kdirect | Jan 10, 2025 | Jan 13, 2025 | Form 4 ↗ |
| TAHL CINDYSee Remarks | Sale | −5,654 | $1.55 | $9K | 336.7Kdirect | Jan 10, 2025 | Jan 13, 2025 | Form 4 ↗ |
| Valamehr BahramPresident and CEO · Director | Sale | −8,705 | $1.54 | $13K | 349.4Kdirect | Jan 10, 2025 | Jan 13, 2025 | Form 4 ↗ |
| Green JeremyDirector · 10% owner | Purchase | +398.0K | $1.68 | $669K | 12.9Mindirect | Dec 20, 2024 | Dec 26, 2024 | Form 4 ↗ |
| Green JeremyDirector · 10% owner | Sale | −341.6K | $1.68 | $574K | 12.5Mindirect | Dec 20, 2024 | Dec 26, 2024 | Form 4 ↗ |
| Xu YuanDirector | Sale | −633 | $4.23 | $3K | 8,669direct | Aug 6, 2024 | Aug 7, 2024 | Form 4 ↗ |
| Dulac Edward J IIIChief Financial Officer | Sale | −2,447 | $7.77 | $19K | 101.5Kdirect | Mar 4, 2024 | Mar 5, 2024 | Form 4 ↗ |
| Dulac Edward J IIIChief Financial Officer | Sale | −1,849 | $5.00 | $9K | 103.9Kdirect | Jan 29, 2024 | Jan 30, 2024 | Form 4 ↗ |
| TAHL CINDYGeneral Counsel and Secretary | Sale | −10.9K | $4.37 | $48K | 142.4Kdirect | Jan 9, 2024 | Jan 10, 2024 | Form 4 ↗ |
| Valamehr BahramChief R&D Officer | Sale | −11.3K | $4.38 | $49K | 158.1Kdirect | Jan 9, 2024 | Jan 10, 2024 | Form 4 ↗ |
| Wolchko J ScottPresident and CEO · Director | Sale | −14.4K | $4.37 | $63K | 371.2Kdirect | Jan 9, 2024 | Jan 10, 2024 | Form 4 ↗ |
| Dulac Edward J IIIChief Financial Officer | Sale | −7,028 | $4.37 | $31K | 105.8Kdirect | Jan 9, 2024 | Jan 10, 2024 | Form 4 ↗ |
| Dulac Edward J IIIChief Financial Officer | Sale | −5,182 | $3.66 | $19K | 112.8Kdirect | Jan 2, 2024 | Jan 3, 2024 | Form 4 ↗ |
| Redmile Group, LLCDirector · 10% owner | Purchase | +44.6K | $3.72 | $166K | 13.2Mindirect | Dec 26, 2023 | Dec 28, 2023 | Form 4 ↗ |
| Dulac Edward J IIIChief Financial Officer | Sale | −1,585 | $3.50 | $6K | 118.0Kdirect | Dec 18, 2023 | Dec 19, 2023 | Form 4 ↗ |
| TAHL CINDYGeneral Counsel and Secretary | Sale | −24.4K | $2.40 | $58K | 153.2Kdirect | Nov 9, 2023 | Nov 13, 2023 | Form 4 ↗ |
| Dulac Edward J IIIChief Financial Officer | Sale | −4,718 | $2.80 | $13K | 119.6Kdirect | Aug 18, 2023 | Aug 21, 2023 | Form 4 ↗ |
| Xu YuanDirector | Sale | −632 | $3.71 | $2K | 9,302direct | Aug 4, 2023 | Aug 7, 2023 | Form 4 ↗ |
| Powl Brian T.Chief Commercial Officer | Sale | −3,854 | $4.87 | $19K | 41.1Kdirect | Jul 5, 2023 | Jul 6, 2023 | Form 4 ↗ |
| Dulac Edward J IIIChief Financial Officer | Sale | −5,182 | $4.83 | $25K | 124.3Kdirect | Jul 5, 2023 | Jul 6, 2023 | Form 4 ↗ |
| Xu YuanDirector | Sale | −3,460 | $5.58 | $19K | 9,934direct | Jun 14, 2023 | Jun 15, 2023 | Form 4 ↗ |
| Green JeremyDirector · 10% owner | Purchase | +256.6K | $6.18 | $1.6M | 13.1Mindirect | Apr 21, 2023 | Apr 21, 2023 | Form 4 ↗ |
| Green JeremyDirector · 10% owner | Purchase | +20.0K | $5.99 | $120K | 12.9Mindirect | Apr 20, 2023 | Apr 21, 2023 | Form 4 ↗ |
| Chu Yu-WayeChief Medical Officer | Sale | −2,317 | $6.58 | $15K | 140.7Kdirect | Apr 18, 2023 | Apr 19, 2023 | Form 4 ↗ |
| Chu Yu-WayeChief Medical Officer | Sale | −215 | $6.52 | $1K | 143.0Kdirect | Apr 18, 2023 | Apr 19, 2023 | Form 4 ↗ |
| Green JeremyDirector · 10% owner | Purchase | +25.7K | $6.00 | $154K | 12.9Mindirect | Apr 14, 2023 | Apr 17, 2023 | Form 4 ↗ |
| Green JeremyDirector · 10% owner | Sale | −302.3K | $5.84 | $1.8M | 12.8Mindirect | Apr 14, 2023 | Apr 17, 2023 | Form 4 ↗ |
| MENDLEIN JOHNDirector | Purchase | +36.6K | $5.43 | $199K | 282.8Kdirect | Jan 13, 2023 | Jan 13, 2023 | Form 4 ↗ |
| MENDLEIN JOHNDirector | Purchase | +88.0K | $5.67 | $499K | 246.1Kdirect | Jan 11, 2023 | Jan 13, 2023 | Form 4 ↗ |
| Wolchko J ScottPresident and CEO · Director | Sale | −45.9K | $5.24 | $241K | 385.6Kdirect | Jan 10, 2023 | Jan 11, 2023 | Form 4 ↗ |
| Valamehr BahramChief R&D Officer | Sale | −10.9K | $5.24 | $57K | 168.9Kdirect | Jan 10, 2023 | Jan 11, 2023 | Form 4 ↗ |
| TAHL CINDYGeneral Counsel and Secretary | Sale | −11.6K | $5.24 | $61K | 177.6Kdirect | Jan 10, 2023 | Jan 11, 2023 | Form 4 ↗ |
| Plavsic MarkChief Technical Officer | Sale | −3,418 | $5.24 | $18K | 123.7Kdirect | Jan 10, 2023 | Jan 11, 2023 | Form 4 ↗ |
| Dulac Edward J IIIChief Financial Officer | Sale | −7,331 | $5.24 | $38K | 129.5Kdirect | Jan 10, 2023 | Jan 11, 2023 | Form 4 ↗ |
| Chu Yu-WayeChief Medical Officer | Sale | −7,825 | $5.24 | $41K | 143.2Kdirect | Jan 10, 2023 | Jan 11, 2023 | Form 4 ↗ |
| Dulac Edward J IIIChief Financial Officer | Sale | −432 | $30.41 | $13K | 136.8Kdirect | Aug 18, 2022 | Aug 19, 2022 | Form 4 ↗ |
| Dulac Edward J IIIChief Financial Officer | Sale | −4,703 | $29.75 | $140K | 137.2Kdirect | Aug 18, 2022 | Aug 19, 2022 | Form 4 ↗ |
| Wolchko J ScottPresident and CEO · Director | Sale | −620 | $33.28 | $21K | 431.5Kdirect | Jul 22, 2022 | Jul 25, 2022 | Form 4 ↗ |
| Wolchko J ScottPresident and CEO · Director | Sale | −2,703 | $32.61 | $88K | 432.2Kdirect | Jul 22, 2022 | Jul 25, 2022 | Form 4 ↗ |
| Wolchko J ScottPresident and CEO · Director | Sale | −2,923 | $31.33 | $92K | 434.9Kdirect | Jul 22, 2022 | Jul 25, 2022 | Form 4 ↗ |
| Wolchko J ScottPresident and CEO · Director | Sale | −19.2K | $33.07 | $634K | 431.5Kdirect | Jul 21, 2022 | Jul 25, 2022 | Form 4 ↗ |
| Wolchko J ScottPresident and CEO · Director | Sale | −10.8K | $32.54 | $352K | 450.7Kdirect | Jul 21, 2022 | Jul 25, 2022 | Form 4 ↗ |
| Valamehr BahramChief R&D Officer | Sale | −17.2K | $30.23 | $519K | 179.8Kdirect | Jul 7, 2022 | Jul 8, 2022 | Form 4 ↗ |
| Valamehr BahramChief R&D Officer | Sale | −7,842 | $30.07 | $236K | 179.8Kdirect | Jul 6, 2022 | Jul 7, 2022 | Form 4 ↗ |
| Plavsic MarkChief Technical Officer | Sale | −3,719 | $24.61 | $92K | 127.1Kdirect | Jul 5, 2022 | Jul 6, 2022 | Form 4 ↗ |
| Agarwal ShefaliDirector | Sale | −841 | $21.89 | $18K | 1,840direct | Jun 7, 2022 | Jun 8, 2022 | Form 4 ↗ |
| Agarwal ShefaliDirector | Sale Amended | −0 | $0.00 | $0 | 2,681direct | Jun 3, 2022 | Jun 8, 2022 | Form 4 ↗ |
| MENDLEIN JOHNDirector | Sale | −1,364 | $22.79 | $31K | 158.1Kdirect | Jun 3, 2022 | Jun 6, 2022 | Form 4 ↗ |
| Jooss KarinDirector | Sale | −1,483 | $22.82 | $34K | 1,198direct | Jun 3, 2022 | Jun 6, 2022 | Form 4 ↗ |
| HERSHBERG ROBERTDirector | Sale | −672 | $22.75 | $15K | 2,009direct | Jun 3, 2022 | Jun 6, 2022 | Form 4 ↗ |
| COUGHLIN TIMOTHYDirector | Sale | −1,439 | $22.81 | $33K | 57.6Kdirect | Jun 3, 2022 | Jun 6, 2022 | Form 4 ↗ |
| Agarwal ShefaliDirector | Sale | −807 | $22.80 | $18K | 1,874direct | Jun 3, 2022 | Jun 6, 2022 | Form 4 ↗ |
| TAHL CINDYGeneral Counsel and Secretary | Sale | −25.0K | $22.96 | $574K | 189.2Kdirect | Jun 1, 2022 | Jun 2, 2022 | Form 4 ↗ |
| Wolchko J ScottPresident and CEO · Director | Sale | −838 | $35.15 | $29K | 431.5Kdirect | Apr 22, 2022 | Apr 25, 2022 | Form 4 ↗ |
| Wolchko J ScottPresident and CEO · Director | Sale | −9,162 | $34.54 | $316K | 432.4Kdirect | Apr 22, 2022 | Apr 25, 2022 | Form 4 ↗ |
| Wolchko J ScottPresident and CEO · Director | Sale | −1,003 | $37.90 | $38K | 431.5Kdirect | Apr 21, 2022 | Apr 25, 2022 | Form 4 ↗ |
| Wolchko J ScottPresident and CEO · Director | Sale | −2,220 | $36.70 | $81K | 432.5Kdirect | Apr 21, 2022 | Apr 25, 2022 | Form 4 ↗ |
| Wolchko J ScottPresident and CEO · Director | Sale | −4,062 | $35.73 | $145K | 434.8Kdirect | Apr 21, 2022 | Apr 25, 2022 | Form 4 ↗ |
| Wolchko J ScottPresident and CEO · Director | Sale | −22.7K | $34.57 | $785K | 438.8Kdirect | Apr 21, 2022 | Apr 25, 2022 | Form 4 ↗ |
| Chu Yu-WayeChief Medical Officer | Sale | −4,062 | $35.37 | $144K | 151.0Kdirect | Apr 19, 2022 | Apr 21, 2022 | Form 4 ↗ |
| TAHL CINDYGeneral Counsel and Secretary | Sale | −25.0K | $38.85 | $971K | 189.2Kdirect | Apr 1, 2022 | Apr 4, 2022 | Form 4 ↗ |
| Valamehr BahramChief R&D Officer | Sale | −100 | $34.04 | $3K | 179.8Kdirect | Mar 14, 2022 | Mar 15, 2022 | Form 4 ↗ |
| Valamehr BahramChief R&D Officer | Sale | −2,960 | $33.30 | $99K | 179.9Kdirect | Mar 14, 2022 | Mar 15, 2022 | Form 4 ↗ |
| Valamehr BahramChief R&D Officer | Sale | −2,195 | $32.49 | $71K | 182.9Kdirect | Mar 14, 2022 | Mar 15, 2022 | Form 4 ↗ |
| Valamehr BahramChief R&D Officer | Sale | −3,067 | $31.66 | $97K | 185.1Kdirect | Mar 14, 2022 | Mar 15, 2022 | Form 4 ↗ |
| Valamehr BahramChief R&D Officer | Sale | −16.7K | $30.36 | $506K | 188.2Kdirect | Mar 14, 2022 | Mar 15, 2022 | Form 4 ↗ |
| MENDLEIN JOHNDirector | Sale | −12.1K | $35.48 | $428K | 159.5Kdirect | Mar 10, 2022 | Mar 11, 2022 | Form 4 ↗ |
| MENDLEIN JOHNDirector | Sale | −19.5K | $34.73 | $677K | 171.5Kdirect | Mar 10, 2022 | Mar 11, 2022 | Form 4 ↗ |
| Wolchko J ScottPresident and CEO · Director | Sale | −10.0K | $38.02 | $380K | 431.5Kdirect | Jan 21, 2022 | Jan 24, 2022 | Form 4 ↗ |
| Wolchko J ScottPresident and CEO · Director | Sale | −30.0K | $40.21 | $1.2M | 431.5Kdirect | Jan 20, 2022 | Jan 24, 2022 | Form 4 ↗ |
| Wolchko J ScottPresident and CEO · Director | Sale | −4,519 | $49.07 | $222K | 431.5Kdirect | Jan 11, 2022 | Jan 13, 2022 | Form 4 ↗ |
| Wolchko J ScottPresident and CEO · Director | Sale | −10.0K | $48.50 | $487K | 436.1Kdirect | Jan 11, 2022 | Jan 13, 2022 | Form 4 ↗ |
| TAHL CINDYGeneral Counsel and Secretary | Sale | −536 | $49.15 | $26K | 155.8Kdirect | Jan 11, 2022 | Jan 13, 2022 | Form 4 ↗ |
| TAHL CINDYGeneral Counsel and Secretary | Sale | −4,883 | $48.46 | $237K | 156.4Kdirect | Jan 11, 2022 | Jan 13, 2022 | Form 4 ↗ |
| Valamehr BahramChief R&D Officer | Sale | −418 | $49.12 | $21K | 146.5Kdirect | Jan 11, 2022 | Jan 13, 2022 | Form 4 ↗ |
| Valamehr BahramChief R&D Officer | Sale | −4,152 | $48.44 | $201K | 146.9Kdirect | Jan 11, 2022 | Jan 13, 2022 | Form 4 ↗ |
| Dulac Edward J IIIChief Financial Officer | Sale | −390 | $49.16 | $19K | 108.6Kdirect | Jan 11, 2022 | Jan 13, 2022 | Form 4 ↗ |
| Dulac Edward J IIIChief Financial Officer | Sale | −1,380 | $48.25 | $67K | 109.0Kdirect | Jan 11, 2022 | Jan 13, 2022 | Form 4 ↗ |
| Chu Yu-WayeSenior VP Clinical Development | Sale | −418 | $49.10 | $21K | 121.8Kdirect | Jan 11, 2022 | Jan 13, 2022 | Form 4 ↗ |
| Chu Yu-WayeSenior VP Clinical Development | Sale | −3,547 | $48.44 | $172K | 122.2Kdirect | Jan 11, 2022 | Jan 13, 2022 | Form 4 ↗ |
| Wolchko J ScottPresident and CEO · Director | Sale | −101 | $47.72 | $5K | 446.1Kdirect | Jan 10, 2022 | Jan 12, 2022 | Form 4 ↗ |
| Wolchko J ScottPresident and CEO · Director | Sale | −20.9K | $47.17 | $986K | 446.2Kdirect | Jan 10, 2022 | Jan 12, 2022 | Form 4 ↗ |
| Wolchko J ScottPresident and CEO · Director | Sale | −13.2K | $46.36 | $610K | 467.1Kdirect | Jan 10, 2022 | Jan 12, 2022 | Form 4 ↗ |
| TAHL CINDYGeneral Counsel and Secretary | Sale | −643 | $47.15 | $30K | 161.3Kdirect | Jan 10, 2022 | Jan 12, 2022 | Form 4 ↗ |
| TAHL CINDYGeneral Counsel and Secretary | Sale | −7,095 | $46.37 | $329K | 161.9Kdirect | Jan 10, 2022 | Jan 12, 2022 | Form 4 ↗ |
| Valamehr BahramChief R&D Officer | Sale | −351 | $47.17 | $17K | 151.1Kdirect | Jan 10, 2022 | Jan 12, 2022 | Form 4 ↗ |
| Valamehr BahramChief R&D Officer | Sale | −5,245 | $46.33 | $243K | 151.5Kdirect | Jan 10, 2022 | Jan 12, 2022 | Form 4 ↗ |
| TAHL CINDYGeneral Counsel and Secretary | Sale | −861 | $60.31 | $52K | 169.0Kdirect | Jan 3, 2022 | Jan 4, 2022 | Form 4 ↗ |
| TAHL CINDYGeneral Counsel and Secretary | Sale | −27.8K | $59.86 | $1.7M | 169.9Kdirect | Jan 3, 2022 | Jan 4, 2022 | Form 4 ↗ |
| TAHL CINDYGeneral Counsel and Secretary | Sale | −16.9K | $58.84 | $994K | 197.7Kdirect | Jan 3, 2022 | Jan 4, 2022 | Form 4 ↗ |
| TAHL CINDYGeneral Counsel and Secretary | Sale | −4,427 | $57.76 | $256K | 214.6Kdirect | Jan 3, 2022 | Jan 4, 2022 | Form 4 ↗ |
| Dulac Edward J IIIChief Financial Officer | Sale | −16.0K | $60.00 | $959K | 110.4Kdirect | Dec 20, 2021 | Dec 21, 2021 | Form 4 ↗ |
| Valamehr BahramChief R&D Officer | Sale | −1,600 | $49.27 | $79K | 156.7Kdirect | Dec 13, 2021 | Dec 14, 2021 | Form 4 ↗ |
| Valamehr BahramChief R&D Officer | Sale | −7,718 | $48.75 | $376K | 158.3Kdirect | Dec 13, 2021 | Dec 14, 2021 | Form 4 ↗ |
| Valamehr BahramChief R&D Officer | Sale | −6,564 | $47.61 | $313K | 166.0Kdirect | Dec 13, 2021 | Dec 14, 2021 | Form 4 ↗ |
| Valamehr BahramChief R&D Officer | Sale | −7,018 | $46.72 | $328K | 172.6Kdirect | Dec 13, 2021 | Dec 14, 2021 | Form 4 ↗ |
| Valamehr BahramChief R&D Officer | Sale | −2,100 | $45.68 | $96K | 179.6Kdirect | Dec 13, 2021 | Dec 14, 2021 | Form 4 ↗ |
| Chu Yu-WayeSenior VP Clinical Development | Sale | −5 | $55.54 | $278 | 125.8Kdirect | Dec 10, 2021 | Dec 13, 2021 | Form 4 ↗ |
| Chu Yu-WayeSenior VP Clinical Development | Sale | −600 | $54.58 | $33K | 126.8Kdirect | Dec 10, 2021 | Dec 13, 2021 | Form 4 ↗ |
| Chu Yu-WayeSenior VP Clinical Development | Sale | −1,031 | $53.66 | $55K | 126.4Kdirect | Dec 10, 2021 | Dec 13, 2021 | Form 4 ↗ |
| Chu Yu-WayeSenior VP Clinical Development | Sale | −1,822 | $52.37 | $95K | 127.4Kdirect | Dec 10, 2021 | Dec 13, 2021 | Form 4 ↗ |
| Chu Yu-WayeSenior VP Clinical Development | Sale | −1,045 | $51.08 | $53K | 129.2Kdirect | Dec 10, 2021 | Dec 13, 2021 | Form 4 ↗ |
| Chu Yu-WayeSenior VP Clinical Development | Sale | −900 | $50.42 | $45K | 130.3Kdirect | Dec 10, 2021 | Dec 13, 2021 | Form 4 ↗ |
| Chu Yu-WayeSenior VP Clinical Development | Sale | −2,097 | $49.32 | $103K | 131.2Kdirect | Dec 10, 2021 | Dec 13, 2021 | Form 4 ↗ |
| Wolchko J ScottPresident and CEO · Director | Sale | −20.0K | $54.27 | $1.1M | 393.8Kdirect | Nov 18, 2021 | Nov 22, 2021 | Form 4 ↗ |
| Wolchko J ScottPresident and CEO · Director | Sale | −30.0K | $58.88 | $1.8M | 393.8Kdirect | Oct 22, 2021 | Oct 25, 2021 | Form 4 ↗ |
| Wolchko J ScottPresident and CEO · Director | Sale | −14.8K | $60.63 | $895K | 393.8Kdirect | Oct 21, 2021 | Oct 25, 2021 | Form 4 ↗ |
| Wolchko J ScottPresident and CEO · Director | Sale | −15.2K | $59.82 | $911K | 408.6Kdirect | Oct 21, 2021 | Oct 25, 2021 | Form 4 ↗ |
| TAHL CINDYGeneral Counsel and Secretary | Sale | −11.8K | $59.68 | $707K | 108.0Kdirect | Oct 1, 2021 | Oct 4, 2021 | Form 4 ↗ |
| TAHL CINDYGeneral Counsel and Secretary | Sale | −21.8K | $58.96 | $1.3M | 119.9Kdirect | Oct 1, 2021 | Oct 4, 2021 | Form 4 ↗ |
| TAHL CINDYGeneral Counsel and Secretary | Sale | −16.3K | $58.03 | $947K | 141.7Kdirect | Oct 1, 2021 | Oct 4, 2021 | Form 4 ↗ |
| Dulac Edward J IIIChief Financial Officer | Sale | −19.5K | $62.53 | $1.2M | 52.4Kdirect | Sep 28, 2021 | Sep 30, 2021 | Form 4 ↗ |
| Valamehr BahramChief Development Officer | Sale | −800 | $67.46 | $54K | 95.7Kdirect | Sep 13, 2021 | Sep 14, 2021 | Form 4 ↗ |
| Valamehr BahramChief Development Officer | Sale | −8,391 | $66.84 | $561K | 96.5Kdirect | Sep 13, 2021 | Sep 14, 2021 | Form 4 ↗ |
| Valamehr BahramChief Development Officer | Sale | −15.8K | $65.94 | $1.0M | 104.9Kdirect | Sep 13, 2021 | Sep 14, 2021 | Form 4 ↗ |
| Wolchko J ScottPresident and CEO · Director | Sale | −20.0K | $88.01 | $1.8M | 393.8Kdirect | Aug 19, 2021 | Aug 20, 2021 | Form 4 ↗ |
| Dulac Edward J IIIChief Financial Officer | Sale | −63 | $90.00 | $6K | 54.5Kdirect | Aug 19, 2021 | Aug 20, 2021 | Form 4 ↗ |
| Dulac Edward J IIIChief Financial Officer | Sale | −1,474 | $88.65 | $131K | 54.6Kdirect | Aug 19, 2021 | Aug 20, 2021 | Form 4 ↗ |
| Dulac Edward J IIIChief Financial Officer | Sale | −1,937 | $87.90 | $170K | 56.1Kdirect | Aug 19, 2021 | Aug 20, 2021 | Form 4 ↗ |
| Wolchko J ScottPresident and CEO · Director | Sale | −30.0K | $85.28 | $2.6M | 393.8Kdirect | Jul 23, 2021 | Jul 26, 2021 | Form 4 ↗ |
| Wolchko J ScottPresident and CEO · Director | Sale | −1,600 | $86.90 | $139K | 393.8Kdirect | Jul 22, 2021 | Jul 26, 2021 | Form 4 ↗ |
| Wolchko J ScottPresident and CEO · Director | Sale | −21.8K | $86.19 | $1.9M | 395.4Kdirect | Jul 22, 2021 | Jul 26, 2021 | Form 4 ↗ |
| Wolchko J ScottPresident and CEO · Director | Sale | −6,627 | $85.38 | $566K | 417.2Kdirect | Jul 22, 2021 | Jul 26, 2021 | Form 4 ↗ |
| TAHL CINDYGeneral Counsel and Secretary | Sale | −50.0K | $84.56 | $4.2M | 108.0Kdirect | Jul 1, 2021 | Jul 2, 2021 | Form 4 ↗ |
| TAHL CINDYGeneral Counsel and Secretary | Sale | −100 | $95.30 | $10K | 158.0Kdirect | Jul 1, 2021 | Jul 2, 2021 | Form 4 ↗ |
| TAHL CINDYGeneral Counsel and Secretary | Sale | −1,825 | $94.63 | $173K | 158.1Kdirect | Jul 1, 2021 | Jul 2, 2021 | Form 4 ↗ |
| TAHL CINDYGeneral Counsel and Secretary | Sale | −400 | $93.31 | $37K | 160.0Kdirect | Jul 1, 2021 | Jul 2, 2021 | Form 4 ↗ |
| TAHL CINDYGeneral Counsel and Secretary | Sale | −432 | $92.26 | $40K | 160.4Kdirect | Jul 1, 2021 | Jul 2, 2021 | Form 4 ↗ |
| TAHL CINDYGeneral Counsel and Secretary | Sale | −225 | $91.06 | $20K | 160.8Kdirect | Jul 1, 2021 | Jul 2, 2021 | Form 4 ↗ |
| TAHL CINDYGeneral Counsel and Secretary | Sale | −707 | $90.30 | $64K | 161.0Kdirect | Jul 1, 2021 | Jul 2, 2021 | Form 4 ↗ |
| TAHL CINDYGeneral Counsel and Secretary | Sale | −400 | $88.93 | $36K | 161.7Kdirect | Jul 1, 2021 | Jul 2, 2021 | Form 4 ↗ |
| TAHL CINDYGeneral Counsel and Secretary | Sale | −1,145 | $87.90 | $101K | 162.1Kdirect | Jul 1, 2021 | Jul 2, 2021 | Form 4 ↗ |
| TAHL CINDYGeneral Counsel and Secretary | Sale | −200 | $86.56 | $17K | 163.3Kdirect | Jul 1, 2021 | Jul 2, 2021 | Form 4 ↗ |
| TAHL CINDYGeneral Counsel and Secretary | Sale | −100 | $84.83 | $8K | 163.5Kdirect | Jul 1, 2021 | Jul 2, 2021 | Form 4 ↗ |
| Valamehr BahramChief Development Officer | Sale | −400 | $90.76 | $36K | 95.7Kdirect | Jun 14, 2021 | Jun 16, 2021 | Form 4 ↗ |
| Valamehr BahramChief Development Officer | Sale | −8,220 | $89.68 | $737K | 96.1Kdirect | Jun 14, 2021 | Jun 16, 2021 | Form 4 ↗ |
| Valamehr BahramChief Development Officer | Sale | −16.4K | $89.11 | $1.5M | 104.4Kdirect | Jun 14, 2021 | Jun 16, 2021 | Form 4 ↗ |
| Wolchko J ScottPresident and CEO · Director | Sale | −20.0K | $77.16 | $1.5M | 393.8Kdirect | May 20, 2021 | May 24, 2021 | Form 4 ↗ |
| Wolchko J ScottPresident and CEO · Director | Sale | −30.0K | $85.24 | $2.6M | 393.8Kdirect | Apr 23, 2021 | Apr 26, 2021 | Form 4 ↗ |
| Wolchko J ScottPresident and CEO · Director | Sale | −30.0K | $85.54 | $2.6M | 393.8Kdirect | Apr 22, 2021 | Apr 26, 2021 | Form 4 ↗ |
| Chu Yu-WayeSenior VP Clinical Development | Sale | −1,500 | $84.41 | $127K | 64.8Kdirect | Apr 16, 2021 | Apr 20, 2021 | Form 4 ↗ |
| Chu Yu-WayeSenior VP Clinical Development | Sale | −900 | $82.91 | $75K | 66.3Kdirect | Apr 16, 2021 | Apr 20, 2021 | Form 4 ↗ |
| Chu Yu-WayeSenior VP Clinical Development | Sale | −875 | $81.80 | $72K | 67.2Kdirect | Apr 16, 2021 | Apr 20, 2021 | Form 4 ↗ |
| TAHL CINDYSee Remarks | Sale | −400 | $87.45 | $35K | 108.0Kdirect | Apr 1, 2021 | Apr 2, 2021 | Form 4 ↗ |
| TAHL CINDYSee Remarks | Sale | −5,299 | $86.76 | $460K | 108.4Kdirect | Apr 1, 2021 | Apr 2, 2021 | Form 4 ↗ |
| TAHL CINDYSee Remarks | Sale | −4,835 | $85.98 | $416K | 113.7Kdirect | Apr 1, 2021 | Apr 2, 2021 | Form 4 ↗ |
| TAHL CINDYSee Remarks | Sale | −2,200 | $84.48 | $186K | 118.6Kdirect | Apr 1, 2021 | Apr 2, 2021 | Form 4 ↗ |
| TAHL CINDYSee Remarks | Sale | −3,490 | $83.40 | $291K | 120.8Kdirect | Apr 1, 2021 | Apr 2, 2021 | Form 4 ↗ |
| TAHL CINDYSee Remarks | Sale | −4,556 | $82.69 | $377K | 124.3Kdirect | Apr 1, 2021 | Apr 2, 2021 | Form 4 ↗ |
| TAHL CINDYSee Remarks | Sale | −8,220 | $81.48 | $670K | 128.8Kdirect | Apr 1, 2021 | Apr 2, 2021 | Form 4 ↗ |
| TAHL CINDYSee Remarks | Sale | −1,000 | $80.49 | $80K | 137.0Kdirect | Apr 1, 2021 | Apr 2, 2021 | Form 4 ↗ |
| Valamehr BahramChief Development Officer | Sale | −1,018 | $94.59 | $96K | 95.7Kdirect | Mar 15, 2021 | Mar 16, 2021 | Form 4 ↗ |
| Valamehr BahramChief Development Officer | Sale | −3,205 | $93.75 | $300K | 96.8Kdirect | Mar 15, 2021 | Mar 16, 2021 | Form 4 ↗ |
| Valamehr BahramChief Development Officer | Sale | −8,404 | $92.64 | $779K | 100.0Kdirect | Mar 15, 2021 | Mar 16, 2021 | Form 4 ↗ |
| Valamehr BahramChief Development Officer | Sale | −8,416 | $91.94 | $774K | 108.4Kdirect | Mar 15, 2021 | Mar 16, 2021 | Form 4 ↗ |
| Valamehr BahramChief Development Officer | Sale | −3,957 | $90.89 | $360K | 116.8Kdirect | Mar 15, 2021 | Mar 16, 2021 | Form 4 ↗ |
| Shoemaker Daniel DChief Scientific Officer | Sale | −800 | $86.70 | $69K | 73.0Kdirect | Mar 8, 2021 | Mar 9, 2021 | Form 4 ↗ |
| Shoemaker Daniel DChief Scientific Officer | Sale | −2,900 | $85.50 | $248K | 73.8Kdirect | Mar 8, 2021 | Mar 9, 2021 | Form 4 ↗ |
| Shoemaker Daniel DChief Scientific Officer | Sale | −2,728 | $84.20 | $230K | 76.7Kdirect | Mar 8, 2021 | Mar 9, 2021 | Form 4 ↗ |
| Shoemaker Daniel DChief Scientific Officer | Sale | −2,480 | $83.46 | $207K | 79.4Kdirect | Mar 8, 2021 | Mar 9, 2021 | Form 4 ↗ |
| Shoemaker Daniel DChief Scientific Officer | Sale | −2,993 | $81.60 | $244K | 81.9Kdirect | Mar 8, 2021 | Mar 9, 2021 | Form 4 ↗ |
| Shoemaker Daniel DChief Scientific Officer | Sale | −5,174 | $80.73 | $418K | 84.9Kdirect | Mar 8, 2021 | Mar 9, 2021 | Form 4 ↗ |
| Shoemaker Daniel DChief Scientific Officer | Sale | −4,627 | $79.58 | $368K | 90.1Kdirect | Mar 8, 2021 | Mar 9, 2021 | Form 4 ↗ |
| Shoemaker Daniel DChief Scientific Officer | Sale | −3,298 | $78.60 | $259K | 94.7Kdirect | Mar 8, 2021 | Mar 9, 2021 | Form 4 ↗ |
| Wolchko J ScottPresident and CEO · Director | Sale | −5,547 | $103.16 | $572K | 393.8Kdirect | Feb 18, 2021 | Feb 19, 2021 | Form 4 ↗ |
| Wolchko J ScottPresident and CEO · Director | Sale | −8,602 | $102.26 | $880K | 399.3Kdirect | Feb 18, 2021 | Feb 19, 2021 | Form 4 ↗ |
| Wolchko J ScottPresident and CEO · Director | Sale | −2,602 | $101.42 | $264K | 407.9Kdirect | Feb 18, 2021 | Feb 19, 2021 | Form 4 ↗ |
| Wolchko J ScottPresident and CEO · Director | Sale | −1,848 | $100.48 | $186K | 410.5Kdirect | Feb 18, 2021 | Feb 19, 2021 | Form 4 ↗ |
| Wolchko J ScottPresident and CEO · Director | Sale | −1,401 | $99.08 | $139K | 412.4Kdirect | Feb 18, 2021 | Feb 19, 2021 | Form 4 ↗ |
| Wolchko J ScottPresident and CEO · Director | Sale | −3,075 | $100.01 | $308K | 393.8Kdirect | Jan 22, 2021 | Jan 22, 2021 | Form 4 ↗ |
| Wolchko J ScottPresident and CEO · Director | Sale | −6,520 | $99.35 | $648K | 396.9Kdirect | Jan 22, 2021 | Jan 22, 2021 | Form 4 ↗ |
| Wolchko J ScottPresident and CEO · Director | Sale | −7,638 | $98.45 | $752K | 403.4Kdirect | Jan 22, 2021 | Jan 22, 2021 | Form 4 ↗ |
| Wolchko J ScottPresident and CEO · Director | Sale | −12.8K | $97.23 | $1.2M | 411.0Kdirect | Jan 22, 2021 | Jan 22, 2021 | Form 4 ↗ |
| Wolchko J ScottPresident and CEO · Director | Sale | −200 | $106.96 | $21K | 393.8Kdirect | Jan 21, 2021 | Jan 22, 2021 | Form 4 ↗ |
| Wolchko J ScottPresident and CEO · Director | Sale | −645 | $106.03 | $68K | 394.0Kdirect | Jan 21, 2021 | Jan 22, 2021 | Form 4 ↗ |
| Wolchko J ScottPresident and CEO · Director | Sale | −4,271 | $105.25 | $450K | 394.6Kdirect | Jan 21, 2021 | Jan 22, 2021 | Form 4 ↗ |
| Wolchko J ScottPresident and CEO · Director | Sale | −9,156 | $104.13 | $953K | 398.9Kdirect | Jan 21, 2021 | Jan 22, 2021 | Form 4 ↗ |
| Wolchko J ScottPresident and CEO · Director | Sale | −3,895 | $103.23 | $402K | 408.1Kdirect | Jan 21, 2021 | Jan 22, 2021 | Form 4 ↗ |
| Wolchko J ScottPresident and CEO · Director | Sale | −3,300 | $101.91 | $336K | 412.0Kdirect | Jan 21, 2021 | Jan 22, 2021 | Form 4 ↗ |
| Wolchko J ScottPresident and CEO · Director | Sale | −5,993 | $101.09 | $606K | 415.3Kdirect | Jan 21, 2021 | Jan 22, 2021 | Form 4 ↗ |
| Wolchko J ScottPresident and CEO · Director | Sale | −2,540 | $100.16 | $254K | 421.3Kdirect | Jan 21, 2021 | Jan 22, 2021 | Form 4 ↗ |
| TAHL CINDYGeneral Counsel and Secretary | Sale | −200 | $117.07 | $23K | 90.0Kdirect | Jan 19, 2021 | Jan 21, 2021 | Form 4 ↗ |
| TAHL CINDYGeneral Counsel and Secretary | Sale | −4,021 | $115.97 | $466K | 90.2Kdirect | Jan 19, 2021 | Jan 21, 2021 | Form 4 ↗ |
| TAHL CINDYGeneral Counsel and Secretary | Sale | −14.9K | $115.09 | $1.7M | 94.3Kdirect | Jan 19, 2021 | Jan 21, 2021 | Form 4 ↗ |
| TAHL CINDYGeneral Counsel and Secretary | Sale | −15.8K | $114.11 | $1.8M | 109.2Kdirect | Jan 19, 2021 | Jan 21, 2021 | Form 4 ↗ |
| Wolchko J ScottPresident and CEO · Director | Sale | −2,300 | $109.65 | $252K | 350.6Kdirect | Jan 11, 2021 | Jan 12, 2021 | Form 4 ↗ |
| Wolchko J ScottPresident and CEO · Director | Sale | −2,772 | $110.76 | $307K | 352.9Kdirect | Jan 11, 2021 | Jan 12, 2021 | Form 4 ↗ |
| Wolchko J ScottPresident and CEO · Director | Sale | −3,515 | $111.62 | $392K | 355.6Kdirect | Jan 11, 2021 | Jan 12, 2021 | Form 4 ↗ |
| Valamehr BahramChief Development Officer | Sale | −871 | $109.65 | $96K | 77.7Kdirect | Jan 11, 2021 | Jan 12, 2021 | Form 4 ↗ |
| Valamehr BahramChief Development Officer | Sale | −1,051 | $110.76 | $116K | 78.6Kdirect | Jan 11, 2021 | Jan 12, 2021 | Form 4 ↗ |
| Valamehr BahramChief Development Officer | Sale | −1,332 | $111.62 | $149K | 79.6Kdirect | Jan 11, 2021 | Jan 12, 2021 | Form 4 ↗ |
| TAHL CINDYGeneral Counsel and Secretary | Sale | −872 | $109.65 | $96K | 90.0Kdirect | Jan 11, 2021 | Jan 12, 2021 | Form 4 ↗ |
| TAHL CINDYGeneral Counsel and Secretary | Sale | −1,050 | $110.76 | $116K | 90.9Kdirect | Jan 11, 2021 | Jan 12, 2021 | Form 4 ↗ |
| TAHL CINDYGeneral Counsel and Secretary | Sale | −1,332 | $111.62 | $149K | 92.0Kdirect | Jan 11, 2021 | Jan 12, 2021 | Form 4 ↗ |
| Shoemaker Daniel DChief Scientific Officer | Sale | −871 | $109.65 | $96K | 83.6Kdirect | Jan 11, 2021 | Jan 12, 2021 | Form 4 ↗ |
| Shoemaker Daniel DChief Scientific Officer | Sale | −1,050 | $110.76 | $116K | 84.5Kdirect | Jan 11, 2021 | Jan 12, 2021 | Form 4 ↗ |
| Shoemaker Daniel DChief Scientific Officer | Sale | −1,332 | $111.62 | $149K | 85.5Kdirect | Jan 11, 2021 | Jan 12, 2021 | Form 4 ↗ |
| Wolchko J ScottPresident and CEO · Director | Sale | −1,469 | $114.76 | $169K | 359.1Kdirect | Jan 8, 2021 | Jan 12, 2021 | Form 4 ↗ |
| Wolchko J ScottPresident and CEO · Director | Sale | −8,515 | $115.80 | $986K | 360.6Kdirect | Jan 8, 2021 | Jan 12, 2021 | Form 4 ↗ |
| Wolchko J ScottPresident and CEO · Director | Sale | −23.9K | $117.15 | $2.8M | 369.1Kdirect | Jan 8, 2021 | Jan 12, 2021 | Form 4 ↗ |
| Wolchko J ScottPresident and CEO · Director | Sale | −26.9K | $117.60 | $3.2M | 393.1Kdirect | Jan 8, 2021 | Jan 12, 2021 | Form 4 ↗ |
| Valamehr BahramChief Development Officer | Sale | −151 | $114.76 | $17K | 81.0Kdirect | Jan 8, 2021 | Jan 12, 2021 | Form 4 ↗ |
| Valamehr BahramChief Development Officer | Sale | −872 | $115.80 | $101K | 81.1Kdirect | Jan 8, 2021 | Jan 12, 2021 | Form 4 ↗ |
| Valamehr BahramChief Development Officer | Sale | −2,451 | $117.15 | $287K | 82.0Kdirect | Jan 8, 2021 | Jan 12, 2021 | Form 4 ↗ |
| Valamehr BahramChief Development Officer | Sale | −2,756 | $117.60 | $324K | 84.5Kdirect | Jan 8, 2021 | Jan 12, 2021 | Form 4 ↗ |
| TAHL CINDYGeneral Counsel and Secretary | Sale | −151 | $114.76 | $17K | 93.3Kdirect | Jan 8, 2021 | Jan 12, 2021 | Form 4 ↗ |
| TAHL CINDYGeneral Counsel and Secretary | Sale | −872 | $115.80 | $101K | 93.4Kdirect | Jan 8, 2021 | Jan 12, 2021 | Form 4 ↗ |
| TAHL CINDYGeneral Counsel and Secretary | Sale | −2,451 | $117.15 | $287K | 94.3Kdirect | Jan 8, 2021 | Jan 12, 2021 | Form 4 ↗ |
| TAHL CINDYGeneral Counsel and Secretary | Sale | −2,755 | $117.60 | $324K | 96.8Kdirect | Jan 8, 2021 | Jan 12, 2021 | Form 4 ↗ |
| Shoemaker Daniel DChief Scientific Officer | Sale | −151 | $114.76 | $17K | 86.9Kdirect | Jan 8, 2021 | Jan 12, 2021 | Form 4 ↗ |
| Shoemaker Daniel DChief Scientific Officer | Sale | −872 | $115.80 | $101K | 87.0Kdirect | Jan 8, 2021 | Jan 12, 2021 | Form 4 ↗ |
| Shoemaker Daniel DChief Scientific Officer | Sale | −2,451 | $117.15 | $287K | 87.9Kdirect | Jan 8, 2021 | Jan 12, 2021 | Form 4 ↗ |
| Shoemaker Daniel DChief Scientific Officer | Sale | −2,755 | $117.60 | $324K | 90.3Kdirect | Jan 8, 2021 | Jan 12, 2021 | Form 4 ↗ |
| Redmile Group, LLCDirector · 10% owner | Purchase | +327.5K | $85.50 | $28.0M | 13.0Mindirect | Jan 8, 2021 | Jan 12, 2021 | Form 4 ↗ |
| Wolchko J ScottPresident and CEO · Director | Sale | −100 | $93.44 | $9K | 420.0Kdirect | Dec 17, 2020 | Dec 18, 2020 | Form 4 ↗ |
| Wolchko J ScottPresident and CEO · Director | Sale | −2,796 | $92.94 | $260K | 420.1Kdirect | Dec 17, 2020 | Dec 18, 2020 | Form 4 ↗ |
| Wolchko J ScottPresident and CEO · Director | Sale | −13.9K | $91.77 | $1.3M | 422.9Kdirect | Dec 17, 2020 | Dec 18, 2020 | Form 4 ↗ |
| Wolchko J ScottPresident and CEO · Director | Sale | −3,168 | $90.98 | $288K | 436.8Kdirect | Dec 17, 2020 | Dec 18, 2020 | Form 4 ↗ |
| Valamehr BahramChief Development Officer | Sale | −100 | $102.75 | $10K | 87.2Kdirect | Dec 14, 2020 | Dec 15, 2020 | Form 4 ↗ |
| Valamehr BahramChief Development Officer | Sale | −1,006 | $102.06 | $103K | 87.3Kdirect | Dec 14, 2020 | Dec 15, 2020 | Form 4 ↗ |
| Valamehr BahramChief Development Officer | Sale | −400 | $100.97 | $40K | 88.3Kdirect | Dec 14, 2020 | Dec 15, 2020 | Form 4 ↗ |
| Valamehr BahramChief Development Officer | Sale | −3,822 | $99.77 | $381K | 88.7Kdirect | Dec 14, 2020 | Dec 15, 2020 | Form 4 ↗ |
| Valamehr BahramChief Development Officer | Sale | −3,148 | $98.80 | $311K | 92.5Kdirect | Dec 14, 2020 | Dec 15, 2020 | Form 4 ↗ |
| Valamehr BahramChief Development Officer | Sale | −2,946 | $97.70 | $288K | 95.7Kdirect | Dec 14, 2020 | Dec 15, 2020 | Form 4 ↗ |
| Valamehr BahramChief Development Officer | Sale | −11.8K | $96.65 | $1.1M | 98.6Kdirect | Dec 14, 2020 | Dec 15, 2020 | Form 4 ↗ |
| Valamehr BahramChief Development Officer | Sale | −1,813 | $95.89 | $174K | 110.4Kdirect | Dec 14, 2020 | Dec 15, 2020 | Form 4 ↗ |
| Shoemaker Daniel DChief Scientific Officer | Sale | −14.8K | $52.40 | $775K | 93.1Kdirect | Nov 16, 2020 | Nov 16, 2020 | Form 4 ↗ |
| Shoemaker Daniel DChief Scientific Officer | Sale | −5,287 | $51.60 | $273K | 107.9Kdirect | Nov 16, 2020 | Nov 16, 2020 | Form 4 ↗ |
| Shoemaker Daniel DChief Scientific Officer | Sale | −4,932 | $50.37 | $248K | 113.2Kdirect | Nov 16, 2020 | Nov 16, 2020 | Form 4 ↗ |
| Wolchko J ScottPresident and CEO · Director | Sale | −10.2K | $51.03 | $518K | 420.0Kdirect | Nov 13, 2020 | Nov 16, 2020 | Form 4 ↗ |
| Wolchko J ScottPresident and CEO · Director | Sale | −9,846 | $51.03 | $502K | 420.0Kdirect | Nov 13, 2020 | Nov 16, 2020 | Form 4 ↗ |
| Wolchko J ScottPresident and CEO · Director | Sale | −10.0K | $51.03 | $510K | 420.0Kdirect | Nov 13, 2020 | Nov 16, 2020 | Form 4 ↗ |
| Wolchko J ScottPresident and CEO · Director | Sale | −1,864 | $54.47 | $102K | 420.0Kdirect | Nov 12, 2020 | Nov 16, 2020 | Form 4 ↗ |
| Wolchko J ScottPresident and CEO · Director | Sale | −10.8K | $53.98 | $585K | 421.8Kdirect | Nov 12, 2020 | Nov 16, 2020 | Form 4 ↗ |
| Wolchko J ScottPresident and CEO · Director | Sale | −2,088 | $52.66 | $110K | 432.7Kdirect | Nov 12, 2020 | Nov 16, 2020 | Form 4 ↗ |
| Wolchko J ScottPresident and CEO · Director | Sale | −15.2K | $51.61 | $785K | 434.8Kdirect | Nov 12, 2020 | Nov 16, 2020 | Form 4 ↗ |
| TAHL CINDYGeneral Counsel and Secretary | Sale | −2,600 | $51.15 | $133K | 99.5Kdirect | Nov 5, 2020 | Nov 6, 2020 | Form 4 ↗ |
| TAHL CINDYGeneral Counsel and Secretary | Sale | −16.7K | $50.55 | $843K | 102.1Kdirect | Nov 5, 2020 | Nov 6, 2020 | Form 4 ↗ |
| TAHL CINDYGeneral Counsel and Secretary | Sale | −51.5K | $50.41 | $2.6M | 99.5Kdirect | Nov 4, 2020 | Nov 6, 2020 | Form 4 ↗ |
| TAHL CINDYGeneral Counsel and Secretary | Sale | −29.2K | $50.25 | $1.5M | 99.5Kdirect | Oct 16, 2020 | Oct 20, 2020 | Form 4 ↗ |
| TAHL CINDYGeneral Counsel and Secretary | Sale | −6,983 | $41.95 | $293K | 99.5Kdirect | Oct 1, 2020 | Oct 2, 2020 | Form 4 ↗ |
| TAHL CINDYGeneral Counsel and Secretary | Sale | −6,260 | $41.09 | $257K | 106.5Kdirect | Oct 1, 2020 | Oct 2, 2020 | Form 4 ↗ |
| TAHL CINDYGeneral Counsel and Secretary | Sale | −21.8K | $40.26 | $876K | 112.8Kdirect | Oct 1, 2020 | Oct 2, 2020 | Form 4 ↗ |
| Valamehr BahramChief Development Officer | Sale | −600 | $37.49 | $22K | 87.2Kdirect | Sep 14, 2020 | Sep 16, 2020 | Form 4 ↗ |
| Valamehr BahramChief Development Officer | Sale | −7,016 | $36.93 | $259K | 87.8Kdirect | Sep 14, 2020 | Sep 16, 2020 | Form 4 ↗ |
| Valamehr BahramChief Development Officer | Sale | −16.8K | $36.03 | $605K | 94.8Kdirect | Sep 14, 2020 | Sep 16, 2020 | Form 4 ↗ |
| Valamehr BahramChief Development Officer | Sale | −600 | $34.65 | $21K | 111.6Kdirect | Sep 14, 2020 | Sep 16, 2020 | Form 4 ↗ |
| Shoemaker Daniel DChief Scientific Officer | Sale | −5,713 | $37.12 | $212K | 118.1Kdirect | Sep 14, 2020 | Sep 16, 2020 | Form 4 ↗ |
| Shoemaker Daniel DChief Scientific Officer | Sale | −17.9K | $36.11 | $646K | 123.8Kdirect | Sep 14, 2020 | Sep 16, 2020 | Form 4 ↗ |
| Shoemaker Daniel DChief Scientific Officer | Sale | −1,400 | $35.40 | $50K | 141.7Kdirect | Sep 14, 2020 | Sep 16, 2020 | Form 4 ↗ |
| Redmile Group, LLCDirector · 10% owner | Purchase | +1.4M | $28.31 | $40.0M | 12.6Mindirect | Jun 11, 2020 | Jun 17, 2020 | Form 4 ↗ |
| Wolchko J ScottPresident and CEO · Director | Sale | −25.0K | $25.45 | $636K | 420.0Kdirect | Jan 30, 2020 | Feb 3, 2020 | Form 4 ↗ |
| Valamehr BahramChief Development Officer | Sale | −5,700 | $20.69 | $118K | 86.1Kdirect | Jan 8, 2020 | Jan 10, 2020 | Form 4 ↗ |
| TAHL CINDYGeneral Counsel and Secretary | Sale | −5,700 | $20.72 | $118K | 99.5Kdirect | Jan 8, 2020 | Jan 10, 2020 | Form 4 ↗ |
| Shoemaker Daniel DChief Scientific Officer | Sale | −5,700 | $20.70 | $118K | 143.1Kdirect | Jan 8, 2020 | Jan 10, 2020 | Form 4 ↗ |
| Shoemaker Daniel DChief Scientific Officer | Sale | −100 | $20.34 | $2K | 123.8Kdirect | Dec 30, 2019 | Jan 2, 2020 | Form 4 ↗ |
| Shoemaker Daniel DChief Scientific Officer | Sale | −24.9K | $19.49 | $485K | 123.9Kdirect | Dec 30, 2019 | Jan 2, 2020 | Form 4 ↗ |
| Wolchko J ScottPresident and CEO · Director | Sale | −25.0K | $20.17 | $504K | 354.0Kdirect | Dec 20, 2019 | Dec 23, 2019 | Form 4 ↗ |
| Wolchko J ScottPresident and CEO · Director | Sale | −25.0K | $20.08 | $502K | 354.0Kdirect | Dec 19, 2019 | Dec 23, 2019 | Form 4 ↗ |
| Wolchko J ScottPresident and CEO · Director | Sale | −21.0K | $14.44 | $303K | 354.0Kdirect | Oct 15, 2019 | Oct 16, 2019 | Form 4 ↗ |
| Valamehr BahramChief Development Officer | Sale | −6,200 | $14.18 | $88K | 66.8Kdirect | Oct 15, 2019 | Oct 16, 2019 | Form 4 ↗ |
| TAHL CINDYGeneral Counsel and Secretary | Sale | −10.2K | $14.24 | $145K | 80.2Kdirect | Oct 15, 2019 | Oct 16, 2019 | Form 4 ↗ |
| Shoemaker Daniel DChief Scientific Officer | Sale | −11.8K | $14.29 | $169K | 123.8Kdirect | Oct 15, 2019 | Oct 16, 2019 | Form 4 ↗ |
| Green JeremyDirector · 10% owner | Purchase | +857.1K | $17.50 | $15.0M | 11.2Mindirect | Sep 16, 2019 | Sep 17, 2019 | Form 4 ↗ |
| Nashat AmirDirector | Sale | −299 | $22.53 | $7K | 11.0Kindirect | Aug 1, 2019 | Aug 2, 2019 | Form 4 ↗ |
| Nashat AmirDirector | Sale | −204 | $22.53 | $5K | 7,539indirect | Aug 1, 2019 | Aug 2, 2019 | Form 4 ↗ |
| Nashat AmirDirector | Sale | −581 | $22.53 | $13K | 21.4Kindirect | Aug 1, 2019 | Aug 2, 2019 | Form 4 ↗ |
| Nashat AmirDirector | Sale | −29.8K | $22.53 | $671K | 1.1Mindirect | Aug 1, 2019 | Aug 2, 2019 | Form 4 ↗ |
| Nashat AmirDirector | Sale | −302 | $22.53 | $7K | 11.3Kindirect | Jul 31, 2019 | Aug 2, 2019 | Form 4 ↗ |
| Nashat AmirDirector | Sale | −206 | $22.53 | $5K | 7,743indirect | Jul 31, 2019 | Aug 2, 2019 | Form 4 ↗ |
| Nashat AmirDirector | Sale | −586 | $22.53 | $13K | 22.0Kindirect | Jul 31, 2019 | Aug 2, 2019 | Form 4 ↗ |
| Nashat AmirDirector | Sale | −30.0K | $22.53 | $677K | 1.1Mindirect | Jul 31, 2019 | Aug 2, 2019 | Form 4 ↗ |
| Nashat AmirDirector | Sale | −873 | $22.51 | $20K | 11.6Kindirect | Jul 30, 2019 | Jul 30, 2019 | Form 4 ↗ |
| Nashat AmirDirector | Sale | −596 | $22.51 | $13K | 7,949indirect | Jul 30, 2019 | Jul 30, 2019 | Form 4 ↗ |
| Nashat AmirDirector | Sale | −1,696 | $22.51 | $38K | 22.6Kindirect | Jul 30, 2019 | Jul 30, 2019 | Form 4 ↗ |
| Nashat AmirDirector | Sale | −87.0K | $22.51 | $2.0M | 1.2Mindirect | Jul 30, 2019 | Jul 30, 2019 | Form 4 ↗ |
| Nashat AmirDirector | Sale | −3 | $22.50 | $68 | 12.5Kindirect | Jul 29, 2019 | Jul 30, 2019 | Form 4 ↗ |
| Nashat AmirDirector | Sale | −3 | $22.50 | $68 | 8,545indirect | Jul 29, 2019 | Jul 30, 2019 | Form 4 ↗ |
| Nashat AmirDirector | Sale | −6 | $22.50 | $135 | 24.3Kindirect | Jul 29, 2019 | Jul 30, 2019 | Form 4 ↗ |
| Nashat AmirDirector | Sale | −317 | $22.50 | $7K | 1.2Mindirect | Jul 29, 2019 | Jul 30, 2019 | Form 4 ↗ |
| Nashat AmirDirector | Sale | −270 | $22.50 | $6K | 12.5Kindirect | Jul 26, 2019 | Jul 30, 2019 | Form 4 ↗ |
| Nashat AmirDirector | Sale | −184 | $22.50 | $4K | 8,548indirect | Jul 26, 2019 | Jul 30, 2019 | Form 4 ↗ |
| Nashat AmirDirector | Sale | −523 | $22.50 | $12K | 24.3Kindirect | Jul 26, 2019 | Jul 30, 2019 | Form 4 ↗ |
| Nashat AmirDirector | Sale | −26.9K | $22.50 | $604K | 1.2Mindirect | Jul 26, 2019 | Jul 30, 2019 | Form 4 ↗ |
| Nashat AmirDirector | Sale | −192 | $22.51 | $4K | 12.8Kindirect | Jul 24, 2019 | Jul 25, 2019 | Form 4 ↗ |
| Nashat AmirDirector | Sale | −132 | $22.51 | $3K | 8,732indirect | Jul 24, 2019 | Jul 25, 2019 | Form 4 ↗ |
| Nashat AmirDirector | Sale | −374 | $22.51 | $8K | 24.8Kindirect | Jul 24, 2019 | Jul 25, 2019 | Form 4 ↗ |
| Nashat AmirDirector | Sale | −19.2K | $22.51 | $431K | 1.3Mindirect | Jul 24, 2019 | Jul 25, 2019 | Form 4 ↗ |
| Nashat AmirDirector | Sale | −601 | $22.51 | $14K | 13.0Kindirect | Jul 23, 2019 | Jul 25, 2019 | Form 4 ↗ |
| Nashat AmirDirector | Sale | −411 | $22.51 | $9K | 8,864indirect | Jul 23, 2019 | Jul 25, 2019 | Form 4 ↗ |
| Nashat AmirDirector | Sale | −1,167 | $22.51 | $26K | 25.2Kindirect | Jul 23, 2019 | Jul 25, 2019 | Form 4 ↗ |
| Nashat AmirDirector | Sale | −59.9K | $22.51 | $1.3M | 1.3Mindirect | Jul 23, 2019 | Jul 25, 2019 | Form 4 ↗ |
Source: SEC EDGAR Form 4 and Form 5 filings, SEC's quarterly bulk dataset through Jun 30, 2026, and KeyVex's half-hourly read of new filings since. Every row links its filing. Amendments are marked. Nothing here is a recommendation. All insider activity, market-wide →